Price · as of 2025-09-30
$2.26
Market cap 41.41M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $25.19 | +1,014.6% |
| Intrinsic Value(DCF) | — | — |
| Graham-Dodd Method(GD) | — | — |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $41.47 | $53.01 | $3.40 | $0.00 | $0.00 |
| 2012 | $64.91 | $79.97 | $211.75 | $2.83 | $514.16 |
| 2013 | $88.69 | $68.70 | $109.86 | $0.00 | $0.00 |
| 2014 | $37.00 | $361.89 | $9.55 | $0.00 | $0.00 |
| 2015 | $14.10 | $773.67 | $11.60 | $19.20 | $60.76 |
| 2016 | $11.30 | $70.13 | $6.92 | $12.44 | $0.00 |
| 2017 | $10.30 | $1,079.14 | $6.92 | $2.46 | $54.23 |
| 2018 | $13.80 | $3,178.60 | $0.00 | $0.00 | $0.00 |
| 2019 | $22.70 | $136.89 | $148.42 | $0.00 | $0.00 |
| 2020 | $63.60 | $154.28 | $1,687.13 | $0.00 | $0.00 |
| 2021 | $62.50 | $85.65 | $3,230.64 | $23.91 | $48.50 |
| 2022 | $54.70 | $110.68 | $0.00 | $0.00 | $273.04 |
| 2023 | $11.70 | $12.04 | $0.00 | $0.00 | $525.35 |
| 2024 | $7.10 | $72.13 | $0.00 | $0.00 | $0.00 |
| 2025 | $2.49 | $25.19 |
AI valuation
Our deep-learning model estimates Veru Inc.'s (VERU) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $25.19
- Current price
- $2.26
- AI upside
- +1,014.6%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
—
— upside
Graham-Dodd
—
— upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| VERU | Veru Inc. | $2.26 | 41.41M | +1,015% | — | — | — | -1.60 | 1.99 | — | -0.60 | — | 3.18 | 0.00% | — | — | -89.74% | -202.93% | -50.36% | 0.17 | — | 2.43 | 2.35 | 0.36 | -6179.00% | -10000.00% | 3756.00% | -82.38% | -3.86 | -246.33% | 0.00% | 0.00% | 4.46% | -0.86 | -0.71 | — | -15.28 |
| ANVS | Annovis Bio, Inc. | $2.68 | 52.73M | — | — | — | — | 0.00 | 2.28 | — | -0.40 | 0.00 | 2.28 | 0.00% | — | — | -3159092.37% | 361.97% | -203782.88% | 0.00 | -14.40 | 3.59 | 2.72 | 0.40 | 3215955.00% | — | 5468129.00% | -103292.61% | -5641.50 | 296879.29% | 0.00% | 0.00% | 22.63% | -0.40 | 0.00 | — | -16.26 |
| BCAB | BioAtla, Inc. | $0.25 | 14.5M | — | +725% | — | — | -0.24 | 1.17 | 1.52 | 0.43 | — | 1.17 | 91.59% | -672.21% | -634.33% | -164.30% | 204.59% | -81.10% | 0.06 | — | 3.52 | 3.37 | 0.66 | -4419.00% | — | -3091.00% | -429.27% | -4.95 | 199.04% | 0.00% | 0.00% | 0.00% | 0.43 | 0.44 | -2.86 | -16.32 |
| BTAI | BioXcel Therapeutics, Inc… | $1.67 | 36.52M | +9,886% | -19% | — | — | -0.14 | -0.09 | 3.77 | -1.85 | — | -0.09 | 5.43% | -2967.56% | -2630.14% | 79.67% | 333.28% | -106.39% | -1.11 | -4.44 | 1.68 | 1.35 | -1.66 | -7610.00% | 6420.00% | -5354.00% | -843.12% | -3.24 | 356.98% | 0.00% | 0.00% | 0.00% | -1.21 | -1.13 | 36.03 | -28.96 |
| CELU | Celularity Inc. | $1.23 | 29.59M | +3,881% | -60% | — | — | -0.47 | 3.05 | 0.50 | -2.17 | — | -3.47 | 72.36% | -70.75% | -106.77% | -232.51% | -41.90% | -41.86% | 7.79 | -6.12 | 0.38 | 0.27 | -1.56 | -7600.00% | 13811.00% | -8464.00% | -24.37% | -0.12 | -7.17% | 0.00% | 0.00% | 0.00% | -2.48 | -14.48 | 1.75 | -10.21 |
| DYAI | Dyadic International, Inc… | $0.78 | 28.19M | +4,253% | -26% | — | — | -7.32 | 17.21 | 12.16 | -7.12 | — | 17.21 | 65.82% | -168.82% | -166.19% | -139.16% | 396.74% | -64.01% | 2.05 | -13.79 | 4.01 | 3.88 | 0.27 | -1667.00% | 2058.00% | -4091.00% | -9.35% | -1.62 | 267.25% | 0.00% | 0.00% | 0.00% | -6.49 | -9.64 | 10.96 | -9.43 |
| MURA | Mural Oncology plc | $2.04 | 35.38M | — | — | — | — | -0.48 | 0.44 | — | 0.60 | — | 0.44 | 0.00% | — | — | -63.57% | -2282.87% | -54.55% | 0.06 | — | 5.84 | 5.51 | 0.86 | -3902.00% | — | -3493.00% | -209.58% | -4.91 | -2123.95% | 0.00% | 0.00% | 0.00% | 0.54 | 0.58 | — | -1.84 |
| PYPD | PolyPid Ltd. | $4.25 | 43.31M | — | — | — | — | -2.08 | 6.47 | — | -1.91 | — | 6.47 | 0.00% | — | — | -366.29% | -2641.59% | -143.79% | 0.25 | -48.13 | 1.97 | 1.67 | 0.11 | -5743.00% | — | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -1.84 | — | — | -19.64 |
| RNXT | RenovoRx, Inc. | $0.88 | 32.36M | — | — | — | — | -2.56 | 5.04 | 525.37 | -1.43 | — | 5.04 | 100.00% | -25511.63% | -20497.67% | -1192.69% | 333.89% | -183.93% | 0.06 | — | 4.10 | 3.77 | 0.63 | -2600.00% | — | -1093.00% | -40.45% | -4.78 | 278.10% | 0.00% | 0.00% | 25.24% | -1.43 | -1.72 | 365.46 | -8.52 |
| RVPH | Reviva Pharmaceuticals Ho… | $0.21 | 14.64M | — | — | — | — | -1.27 | 46.91 | — | -0.84 | — | 46.91 | 0.00% | — | — | -916.17% | 206.33% | -152.63% | 0.56 | -1665.07 | 1.01 | 0.92 | 0.44 | -4545.00% | — | 1843.00% | -88.00% | -2.30 | 224.72% | 0.00% | 0.00% | 0.00% | -0.82 | -0.75 | — | -19.83 |
About Veru Inc.
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
- CEO
- Mitchell S. Steiner
- Employees
- 210
- Beta
- -1.49
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as (— ÷ $2.26) − 1 = — (DCF, example).